Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
27,433,692
-
Shares change
-
-84,839
-
Total reported value, excl. options
-
$754,721,335
-
Value change
-
-$1,638,080
-
Put/Call ratio
-
105%
-
Number of buys
-
40
-
Number of sells
-
-37
-
Price
-
$27.55
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2017
101 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2017.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27,433,692 shares
of 104,661,494 outstanding shares and own 26% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), JPMORGAN CHASE & CO (3,546,267 shares), FRANKLIN RESOURCES INC (3,288,778 shares), WELLINGTON MANAGEMENT GROUP LLP (2,341,510 shares), BlackRock Inc. (2,165,600 shares), ArrowMark Colorado Holdings LLC (2,135,521 shares), Bank of New York Mellon Corp (2,009,312 shares), Polar Capital LLP (1,424,213 shares), VANGUARD GROUP INC (1,024,335 shares), and CANADA PENSION PLAN INVESTMENT BOARD (582,900 shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.